Revista do Instituto de Medicina Tropical de São Paulo · 1997 · 25 citations · 11 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceMedical MicrobiologyVirologyAntifungal AgentsAntifungal PharmacologyAntifungal PharmacotherapyAntifungal ResistanceAntifungal TherapyFungal InfectionsCandida TherapyCryptococcal MeningitisCryptococcosis TherapyCryptococcus ResistanceFluconazole TherapyFungal Infection TreatmentFungal MeningitisNew Antifungal Agents
Cryptococcus neoformans is the fifth most common opportunistic agent of infection in patients with AIDS in the USA, exceeded only by Candida species, Pneumocystis carinii, cytomegalovirus and Mycobacterium avium1, 2, 6, 10, 11. In Brazil is the sixth, exceeded by Candida species, P. carinii, Mycobacterium species, Toxoplasma gondii, and herpes simplex virus (AIDS, Boletim Epidemiológico, set/nov 96, Ministério da Saúde, Brasil). During 30 years, the treatment of C. neoformans meningitis was based on the use of amphotericin B with or without flucytosine13. Nowadays, with the immunodepression caused by human immunodeficiency virus (HIV) infection and the availability of new antifungal drugs as the triazoles, the concept related to cure and relapses of cryptococcosis has been altered7, 20. Patients are treated with amphotericin B with or without flucytosine as initial therapy, but maintenance therapy is always necessary in AIDS patients with C. neoformans infections
11
Arturo Casadevall, Eric D. Spitzer, Douglas Webb et al. · Antimicrobial Agents and Chemotherapy · 1993 · 104 citations · Full text
Fiona S. Clark, Tanya Parkinson, Christopher A. Hitchcock et al. · Antimicrobial Agents and Chemotherapy · 1996 · 98 citations · Full text